Merrie Mosedale

List of Publications by Year
in descending order

29 papers	2,629 citations	516561 16 h-index	501076 28 g-index
30 all docs	30 docs citations	30 times ranked	4918 citing authors

#	Article	IF	Citations
1	Differential Detergent Fractionation of Membrane Protein From Small Samples of Hepatocytes and Liver Tissue for Quantitative Proteomic Analysis of Drug Metabolizing Enzymes and Transporters. Journal of Pharmaceutical Sciences, 2021, 110, 87-96.	1.6	8
2	Characterization of primary mouse hepatocyte spheroids as a model system to support investigations of drug-induced liver injury. Toxicology in Vitro, 2021, 70, 105010.	1.1	6
3	Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression. Journal of Pharmaceutical Sciences, 2021, 110, 412-421.	1.6	14
4	Human-relevant mechanisms and risk factors for TAK-875-Induced liver injury identified via a gene pathway-based approach in Collaborative Cross mice. Toxicology, 2021, 461, 152902.	2.0	12
5	Shedding Light on Drug-Induced Liver Injury: Activation of T Cells From Drug Naive Human Donors With Tolvaptan and a Hydroxybutyric Acid Metabolite. Toxicological Sciences, 2021, 179, 95-107.	1.4	2
6	Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury. Chemical Research in Toxicology, 2020, 33, 2745-2748.	1.7	13
7	Understanding Idiosyncratic Toxicity: Lessons Learned from Drug-Induced Liver Injury. Journal of Medicinal Chemistry, 2020, 63, 6436-6461.	2.9	34
8	Fit-For-Purpose Hepatocyte Models Enable the Identification of Early Events Contributing to Idelalisib-Induced Liver Injury. Applied in Vitro Toxicology, 2020, 6, 110-119.	0.6	0
9	Identification of Candidate Risk Factor Genes for Human Idelalisib Toxicity Using a Collaborative Cross Approach. Toxicological Sciences, 2019, 172, 265-278.	1.4	22
10	Hepatocyte-Derived Exosomes Promote Liver Immune Tolerance: Possible Implications for Idiosyncratic Drug-Induced Liver Injury. Toxicological Sciences, 2019, 170, 499-508.	1.4	30
11	Bioprinted liver provides early insight into the role of Kupffer cells in TGF-Î²1 and methotrexate-induced fibrogenesis. PLoS ONE, 2019, 14, e0208958.	1.1	59
12	Quantitative Systems Toxicology Analysis ofIn VitroMechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury. Toxicological Sciences, 2019, 167, 458-467.	1.4	35
13	Transient Changes in Hepatic Physiology That Alter Bilirubin and Bile Acid Transport May Explain Elevations in Liver Chemistries Observed in Clinical Trials of GGF2 (Cimaglermin Alfa). Toxicological Sciences, 2018, 161, 401-411.	1.4	17
14	Optimized Methods to Explore the Mechanistic and Biomarker Potential of Hepatocyte-Derived Exosomes in Drug-Induced Liver Injury. Toxicological Sciences, 2018, 163, 92-100.	1.4	13
15	miR-122 Release in Exosomes Precedes Overt Tolvaptan-Induced Necrosis in a Primary Human Hepatocyte Micropatterned Coculture Model. Toxicological Sciences, 2018, 161, 149-158.	1.4	40
16	Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine. American Journal of Pharmaceutical Education, 2018, 82, 6652.	0.7	4
17	Mouse Population-Based Approaches to Investigate Adverse Drug Reactions. Drug Metabolism and Disposition, 2018, 46, 1787-1795.	1.7	7
18	Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. Clinical Pharmacology and Therapeutics, 2017, 102, 961-969.	2.3	29

#	Article	IF	Citations
19	Candidate Risk Factors and Mechanisms for Tolvaptan-Induced Liver Injury Are Identified Using a Collaborative Cross Approach. Toxicological Sciences, 2017, 156, kfw269.	1.4	46
20	Drugâ€induced liver injury: Advances in mechanistic understanding that will inform risk management. Clinical Pharmacology and Therapeutics, 2017, 101, 469-480.	2.3	155
21	Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. Toxicological Sciences, 2017, 155, 61-74.	1.4	71
22	Subtoxic Alterations in Hepatocyte-Derived Exosomes: An Early Step in Drug-Induced Liver Injury?. Toxicological Sciences, 2016, 151, 365-375.	1.4	71
23	Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice. Food and Chemical Toxicology, 2015, 76, 19-26.	1.8	80
24	A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis. Toxicological Sciences, 2014, 140, 481-492.	1.4	44
25	Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug. Toxicology and Applied Pharmacology, 2014, 280, 21-29.	1.3	14
26	PPARÎ³ coactivator-1Î± contributes to exercise-induced regulation of intramuscular lipid droplet programming in mice and humans. Journal of Lipid Research, 2013, 54, 522-534.	2.0	89
27	Neurexin-1Î± Contributes to Insulin-containing Secretory Granule Docking. Journal of Biological Chemistry, 2012, 287, 6350-6361.	1.6	32
28	Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to Skeletal Muscle Insulin Resistance. Cell Metabolism, 2008, 7, 45-56.	7.2	1,618
29	Expression of Neurexin, Neuroligin, and Their Cytoplasmic Binding Partners in the Pancreatic Î²-Cells and the Involvement of Neuroligin in Insulin Secretion. Endocrinology, 2008, 149, 6006-6017.	1.4	64